A new study reveals it Secondary effects of laganem They are managedAccording to researchers at the University of Washington University of America (Washu). The results of this backwards study are published Zama neurology.
It must be remembered that Liganemapin’s Food and Drug Administration (FDA) approval (Alzheimer’s new treatment in 2023 The first drug of this type Can affect the disease.
Suspicion of severe side effects
However, during medical examinations Side effects arose .
That is why researchers at the University of Washington in San Louis have departed Read the adverse effects associated with treatment with Liganmeb In their medical patients and they found that significant adverse effects were rare and restricted. The work was focused on 234 patients with very mild or mild Alzheimer’s disease, and he received Leganem injections at the Washu Medicine Memory Center, a clinic that specializes in the treatment of dementia patients.
In accordance with the results of carefully controlled clinical trials, researchers found it Only 1% of patients experienced severe side -effects It should be hospitalized. Patients in the early stages of Alzheimer with very little symptoms put forward the lowest risk of complications, according to the researchers, which helps patients and medical professionals during conversation on treatment risks.
The only treatment that affects progress
“Early Symptoms of Alzheimer This new type of drugs Affects the progress of the disease ”Points Dr. Barbara Joy Snyder, Professor of Neurology and a key partner of the study.
“However, fear around the potential side effects of the drug Causes delay in treatment. Our study has the infrastructure and experience required to safely manage and serve patients in the outpatient clinic of the Washu Medician, including some who can experience severe side -effects, which opens the way to additional clinics to administer drugs to patients. “
Leganep is an antibody therapy The amyroid plate removes proteinsLonging an independent life in 10 months, according to a recent study, led by Washu Medicine researchers. Since amioid accumulation is the first step in the disease, doctors prescribe medicine for people with very little or minor symptoms for those in the early stages of Alzheimer. Researchers have found that only 1.8% of patients with low symptoms have developed adverse symptoms compared to 27% of patients in mild Alzheimer’s patients.
Contradictions that indicate inflammation and bleeding
“Available in patients with mild symptoms of Alzheimer The greatest benefit and the lowest risk The adverse effects of treatment are, “Snyder says, who directed Lecanmef’s medical examination in Washu medicine.” Hesitating and disadvantage can lead to delaying treatment, which increases the risk of side effects. We hope that the results will help to review the conversations between doctors and patients on the risks of the drug. “
Suspects about Lenmef are called a side effect Image abnormalities associated with amyide (aria). These contraindications usually affect only the smallest part of the brain, appear in brain studies and indicate inflammation or bleeding. In medical examinations with Leganemp, 12.6% of participants experienced ARIA, most cases were unidentified and resolved without intervention. A small percentage (about 2.8%of the treatment participants) experienced symptoms such as headaches, confusion, nausea and dizziness. It is estimated that occasional deaths are associated with liganmef in 0.2% of patients in treatment.
Memory detection center Began to treat patients with Legalm in 2023After receiving the total approval of the FDA. Patients get medication every two weeks in injection centers. As part of the care of each patient, doctors regularly receive sophisticated images to monitor the brain, allowing them to detect bleeding and inflammation with great sense of inflammation. Legonmef is suspended for patients with symptomatic Arya or Aria, and severe ARA patients get steroid treatment at the hospital.
The frequency is in line with those found in tests
When analyzing the results of patients, the authors noticed that the size of the side effects Correspond to medical examinations: Most of the events of ARIA in the clinic are unidentified and are found only by brain studies used to monitor brain changes. Of the 11 patients who experienced Aryan symptoms, the effects were often resolved in a few months, and the patient did not die.
“Most patients receiving leaganamp Tolerate the drug ”Dr. Susain Shindler, the co -professor of neurology and the principal partner of the study. “This report will help patients and health experts better understand the risks of treatment. They are small in patients with the lowest symptoms of Alzheimer.”
Notes
Paxinski M, Hoffman A, Bosy Z, Grekerson M, Rudman M, Ellington D, Aldinger M, Musek ES, Holdsman TM. Legonmef Treatment at a Special Memory Clinic: Possible and Protection. Jama neurology (2025). DOI: 10.1001/jamaneurol.2025.1232
We’re already on WhatsApp! If you want to get all the current messages and the most important messages of the day, Click here and join our channel. It is a free, convenient and safe system.
